2019年06月12日讯 /生物谷BIOON/ --勃林格殷格翰-礼来糖尿病联盟近日在旧金山举行的美国糖尿病协会（ADA2019）第79届科学会议上 ...

（编辑推荐）本文系统综述了二肽基肽酶-4抑制剂（DPP-4I）在2型糖尿病（T2DM）治疗中的机制优势，详述了西格列汀（sitagliptin）、维格列汀（vildagliptin）等5种FDA批准药物的合成策略，突出其低血糖风险小、安全性高等特点，为糖尿病药物研发提供重要参考。

这篇综述通过荟萃分析，探究 DPP-4 抑制剂对 T2DM 合并 NAFLD 患者转氨酶水平的影响。发现其能降低丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平，还改善血糖控制等，不过存在局限性，为临床用药提供参考。 引言 2 型糖尿病（T2DM）和非酒精性脂肪性肝病 ...

Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual ...

As if last week's Jardiance news wasn't enough to worry makers of DPP-4 diabetes drugs, the FDA has now issued a warning that the class of meds might cause "severe and disabling" joint pain. The ...

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes may cause joint pain so intense it is disabling, the US Food and Drug Administration (FDA) warned today. Fortunately, the pain goes away, ...